INTRODUCTION {#s1}
============

Esophageal cancer (EC) is one of the most fatal types of cancer worldwide \[[@R1], [@R2]\]. Esophageal squamous cell carcinoma (ESCC) is the major pathological type in China \[[@R3], [@R4]\]. Although the treatment has been improved in recent years, the prognosis for EC remains poor. Therefore, assessing the prognostic factors in patients with EC will become more important. To date, several biomarkers have been evaluated to predict the prognosis for EC, but the prognostic values remain controversial \[[@R5]\].

Inflammation plays an important role in cancer progression and prognosis \[[@R6], [@R7]\]. Therefore, a series of inflammatory biomarkers, such as c-reactive protein (CRP), neutrophil lymphocyte ratio (NLR) and Glasgow prognostic score (GPS) have been evaluated to predict the prognosis in several cancers \[[@R8]--[@R12]\]. Recently, the CRP/Albumin (CRP/Alb) ratio was reported to correlate with prognosis in various cancers, including EC \[[@R13]--[@R15]\]. However, to our knowledge, no study so far has assessed the clinical significance of the NLR/Albumin (NLR/Alb) ratio in other cancers as well as EC. Therefore, the aim of this study was to investigate the prognostic value of NLR/Alb ratio in patients with resectable ESCC.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

Of the total number of cases, 42 (12.8%) were women and 287 (87.2%) were men. According to the X-tile program, the optimal cut-off values for NLR, CRP, albumin, CRP/Alb and NLR/Alb were 4.0, 12.0 mg/l. 42.0 g/l, 0.1 and 0.1, respectively (Figure [1](#F1){ref-type="fig"}). According to the cut-off value, then patients were divided into two groups: NLR/Alb ≤ 0.1 and NLR/Alb \> 0.1. The relationships between NLR/Alb and clinical characteristics were shown in Table [1](#T1){ref-type="table"}. Our study revealed that NLR/Alb ratio was associated with tumor length (*P* \< 0.001), TNM stage (*P* \< 0.001), NLR (*P* = 0.021), CRP (*P* = 0.002), Alb (*P* \< 0.001), CRP/Alb (*P* = 0.002) and GPS (*P* \< 0.001), respectively.

![X-tile analyses\
X-tile plots of the training sets are shown in the left panels, with plots of matched validation sets shown in the smaller inset. The optimal cut-off point highlighted by the black circle in the left panels is shown on a histogram of the entire cohort (middle panels), and a Kaplan--Meier plot (right panels). According to the X-tile program, the optimal cut-off values for NLR, CRP, albumin, CRP/Alb and NLR/Alb were 4.0, 12.0 mg/l. 42.0 g/l, 0.1 and 0.1, respectively. (NLR = neutrophil lymphocyte ratio; CRP = c-reactive protein; CTA = CRP to albumin; NTA = NLR to albumin)](oncotarget-08-103535-g001){#F1}

###### The relationship between NLR/Alb and clinical characteristics for ESCC

  -------------------------------------------------------------------------------------------------------------------------
                              Total (*N* = 329)\   NLR/Alb ≤ 0.1 (*N* = 238)\   NLR/Alb \> 0.1(*N* = 91)\   *P*-value
                              (*n*, %)             (*n*, %)                     (*n*, %)                    
  --------------------------- -------------------- ---------------------------- --------------------------- ---------------
  Sex\                        287 (87.2)\          207 (87.0)\                  80 (87.9)\                  0.820
   Male\                      42 (12.8)            31 (13.0)                    11 (12.1)                   
   Female                                                                                                   

  Age (years)\                190 (57.8)\          137 (57.6)\                  53 (58.2)\                  0.911
   ≤ 60\                      139 (42.2)           101 (42.4)                   38 (41.8)                   
   \> 60                                                                                                    

  Tumor length (cm)\          92 (28.0)\           82 (34.5)\                   10 (11.0)\                  \< 0.001
   ≤ 3.0\                     237 (72.0)           156 (65.5)                   81 (89.0)                   
   \> 3.0                                                                                                   

  Tumor location\             19 (5.8)\            14 (5.9)\                    5 (5.5)\                    0.345
   Upper\                     154 (46.8)\          117 (49.2)\                  37 (40.7)\                  
   Middle\                    156 (47.4)           107 (44.9)                   49 (53.8)                   
   Lower                                                                                                    

  Vessel invasion\            51 (15.5)\           38 (16.0)\                   13 (14.3)\                  0.706
   Positive\                  278 (84.5)           200 (84.0)                   78 (85.7)                   
   Negative                                                                                                 

  Perineural invasion\        64 (19.5)\           47 (19.7)\                   17 (18.7)\                  0.827
   Positive\                  265 (80.5)           191 (80.3)                   74 (81.3)                   
   Negative                                                                                                 

  Differentiation\            46 (14.0)\           32 (13.4)\                   14 (15.4)\                  0.422
   Well\                      220 (66.9)\          164 (68.9)\                  56 (61.5)\                  
   Moderate\                  63 (19.1)            42 (17.7)                    21 (23.1)                   
   Poor                                                                                                     

  TNM stage\                  85 (25.8)\           77 (32.4)\                   8 (8.8)\                    \< 0.001
   I\                         109 (33.1)\          83 (34.9)\                   26 (28.6)\                  
   II\                        135 (41.1)           78 (32.7)                    57 (62.6)                   
   III                                                                                                      

  Adjuvant therapy\           94 (28.6)\           63 (26.5)\                   31 (34.1)\                  0.173
   Yes\                       235 (71.4)           175 (73.5)                   60 (65.9)                   
   No                                                                                                       

  NLR (mean ± SD)\            3.36 ± 2.27\         2.56 ± 1.25\                 5.45 ± 2.92\                \< 0.001^\*^\
   ≤ 4.0\                     220 (66.9)\          201 (84.5.)\                 19 (20.9.)\                 \< 0.001
   \> 4.0                     109 (33.1)           37 (15.5)                    72 (80.1)                   

  CRP (mg/l, mean ± SD)\      7.42 ± 11.8\         6.20 ± 10.60\                10.6 ± 14.1\                0.007^\*^\
   ≤ 12.0\                    264 (80.2)\          201 (84.5)\                  63 (69.2)\                  0.002
   \> 12.0                    67 (19.8)            37 (15.5)                    28 (30.8)                   

  Albumin (g/l, mean ± SD)\   40.51 ± 5.30\        41.77 ± 4.85\                37.20 ± 5.04\               \< 0.001^\*^\
   ≤ 42.0\                    205 (62.3)\          129 (54.2)\                  76 (83.5)\                  \< 0.001
   \> 42.0                    124 (37.7)           109 (45.8)                   15 (16.5)                   

  CRP/Alb (mean ± SD)\        0.19 ± 0.33\         0.15 ± 0.27\                 0.30 ± 0.43\                \< 0.001^\*^\
   ≤ 0.1\                     175 (53.2)\          139 (58.4)\                  36 (39.6)\                  0.002
   \> 0.1                     154 (46.8)           99 (41.6)                    55 (60.4)                   

  GPS\                        194 (59.0)\          164 (68.9)\                  30 (33.0)\                  \< 0.001
   0\                         95 (28.9)\           65 (27.3)\                   30 (33.0)\                  
   1\                         40 (12.1)            9 (3.8)                      31 (34.0)                   
   2                                                                                                        
  -------------------------------------------------------------------------------------------------------------------------

ESCC = esophageal squamous cell carcinoma; NLR = neutrophil lymphocyte ratio; Alb = albumin; CRP = c-reactive protein; GPS= Glasgow prognostic score Statistical methods: The chi-squared test. "^\*^" by *t*-test.

Pearson correlation {#s2_2}
-------------------

Pearson correlation analyses revealed that there were significant positive correlations between NLR and CRP (r = 0.288, *P* \< 0.001, Figure [2A](#F2){ref-type="fig"}), NLR/Alb and CRP/Alb (r = 0.351, *P* \< 0.001, Figure [2B](#F2){ref-type="fig"}), but negative correlations between NLR and Alb (r = --0.169, *P* = 0.002, Figure [2C](#F2){ref-type="fig"}), CRP and Alb (r = --0.175, *P* = 0.001, Figure [2D](#F2){ref-type="fig"}).

![Pearson correlation analysis\
Positive correlations between NLR and CRP (r = 0.288, *P* \< 0.001, (**A**), between NLR/Alb and CRP/Alb (r = 0.351, *P* \< 0.001, (**B**); negative correlations between NLR and Alb (r = -0.169, *P* = 0.002, (**C**), between CRP and Alb (r = --0.175, *P* = 0.001, (**D**).](oncotarget-08-103535-g002){#F2}

Kaplan--Meier analyses {#s2_3}
----------------------

Kaplan--Meier analyses demonstrated that there was a significantly better 5-year CSS in patients with NLR/Alb ≤ 0.1 than patients with NLR/Alb \> 0.1 (39.1% vs. 11.0%, *P* \< 0.001) (Figure [3A](#F3){ref-type="fig"}). Then, we further stratified patients into different groups based on TNM stage. Our results demonstrated that NLR/Alb ratio was also significantly correlated with CSS based on TNM stage (Figure [3B--3D](#F3){ref-type="fig"}).

![Kaplan--Meier CSS curves stratified by NLR/Alb\
The range duration of follow-up were 3 to 94 months, with the median of 34 months. A significantly better 5-year CSS in patients with NLR/Alb ≤ 0.1 than patients with NLR/Alb \> 0.1 (39.1% vs. 11.0%, *P* \< 0.001; median CSS: 44 months vs. 20 months; (**A**). Patients with NLR/Alb ratio ≤ 0.1 had a significantly better 5-year CSS than patients with NLR/Alb ratio \> 0.1 in TNM I (51.9% vs. 12.5%, *P* = 0.012; median CSS: 78 months vs. 35 months; (**B**), TNM II (38.6% vs. 15.4%, *P* = 0.003; median CSS: 42 months vs. 20 months; (**C**) and TNM III (26.9% vs. 8.8%, *P* = 0.008; median CSS: 23 months vs. 16 months; (**D**).](oncotarget-08-103535-g003){#F3}

Univariate and multivariate analyses {#s2_4}
------------------------------------

In univariate analyses, tumor length (*P* = 0.030), vessel invasion (*P* = 0.010), perineural invasion (*P* = 0.034), TNM stage (*P* \< 0.001), NLR (*P* \< 0.001), CRP (*P* \< 0.001), Alb(*P* = 0.001), GPS (*P* \< 0.001), CRP/Alb (*P* \< 0.001) and NLR/Alb (*P* \< 0.001) were also significant predictors of CSS. Multivariate analyses revealed that NLR/Alb (*P* = 0.001) was an independent prognostic factor (Table [2](#T2){ref-type="table"}). In addition, TNM stage (*P* \< 0.001) and CRP/Alb (*P* \< 0.001) were also significant independent predictors for CSS (Table [2](#T2){ref-type="table"}).

###### Univariate and multivariate analyses for cancer-specific survival

  ------------------------------------------------------------------------------------------------------------
                                       Univariate analyses     *P*-value   Multivariate analyses   *P*-value
  ------------------------------------ ----------------------- ----------- ----------------------- -----------
  Sex (male vs female)                 1.055 (0.710--1.567)    0.791                               

  Age (years, \> 60 vs ≤ 60)           1.023 (0.785--1.332)    0.868                               

  Tumor length (cm, \> 3.0 vs ≤ 3.0)   1.391 (1.032--1.876)    0.030                               

  Tumor location\                      1.000 (Reference)\      0.687\                              
   Upper\                              1.311 (0.705--2.440)\   0.392\                              
   Middle\                             1.302 (0.700--2.422)    0.404                               
   Lower                                                                                           

  Vessel invasion (yes vs no)          1.562 (1.112--2.192)    0.010                               

  Perineural invasion (yes vs no)      1.406 (1.026--1.926)    0.034                               

  Differentiation\                     1.000 (Reference)\      0.216\                              
   Well\                               1.183 (0.790--1.770)\   0.415\                              
   Moderate\                           1.492 (0.931--2.392)    0.097                               
   Poor                                                                                            

  TNM stage\                           1.000 (Reference)\      \< 0.001\   1.000\                  \< 0.001\
   I\                                  1.696 (1.166--2.467)\   0.006\      1.481 (1.014--2.163)\   0.042\
   II\                                 2.654 (1.866--3.774)    \< 0.001    2.129 (1.474--3.074)    \< 0.001
   III                                                                                             

  Adjuvant therapy (yes vs no)         1.116 (0.836--1.488)    0.457                               

  NLR (\> 4.0 vs ≤ 4.0)                2.130 (1.579--2.872)    \< 0.001                            

  CRP (mg/l, \> 12.0 vs ≤ 12.0)        2.037 (1.502--2.761)    \< 0.001                            

  Albumin (g/l, \> 42.0 vs ≤ 42.0)     0.619 (0.467--0.820)    0.001                               

  CRP/Alb (\> 0.1 vs ≤ 0.1)            1.919 (1.473--2.498)    \< 0.001    1.640 (1.248--2.154)    \< 0.001

  GPS\                                 1.000 (Reference)\      \< 0.001\                           
   0\                                  1.960 (1.465--2.623)\   \< 0.001\                           
   1\                                  2.463 (1.676--3.619)    \< 0.001                            
   2                                                                                               

  NLR/Alb (\> 0.1 vs ≤ 0.1)            2.293 (1.741--3.020)    \< 0.001    1.672 (1.245--2.245)    0.001
  ------------------------------------------------------------------------------------------------------------

ESCC = esophageal squamous cell carcinoma; NLR = neutrophil lymphocyte ratio; Alb = albumin; CRP = c-reactive protein; GPS = Glasgow prognostic score; HR = hazard ratio; CI = confidence interval Statistical methods: Univariate and multivariate analyses.

ROC analysis {#s2_5}
------------

The areas under the curve (AUC) was 0.702 (95% CI: 0.635--0.763, *P* \< 0.001) for CRP/Alb and 0.678 (95% CI: 0.574--0.716, *P* \< 0.001) for NLR/Alb, respectively. The discrimination ability of the NLR/Alb was similar to CRP/Alb, indicating that NLR/Alb predicts survival in ESCC similar to CRP/Alb (Figure [4](#F4){ref-type="fig"}).

![ROC curves for CSS prediction\
A ROC curve plots the sensitivity on the y-axis against one minus the specificity on the x-axis. A diagonal line at 45 degrees, known as the line of chance, would result from a test which allocated subjects randomly. Each point on the ROC cueve corresponds to a value by Youden Index (sensitivity+specificity-1). The areas under the curve (AUC) was 0.702 (95% CI: 0.635-0.763, *P* \< 0.001) for CRP/Alb and 0.678 (95% CI: 0.574-0.716, *P* \< 0.001) for NLR/Alb, respectively.](oncotarget-08-103535-g004){#F4}

DISCUSSION {#s3}
==========

As we know, both NLR and Alb are influenced by various conditions, and the ratio of NLR and Alb could therefore minimise the potential basis. To our knowledge, this is the first study to evaluate the prognostic role of NLR/Alb ratio in predicting prognosis for patients with resectable ESCC. In the present study, therefore, a novel inflammation-based prognostic index was conducted based on NLR and Alb and was shown to be an independent predictor for patients with resectable ESCC.

There is strong linkage between inflammation and cancer. As we know, serum CRP is a very sensitive indicator of systemic inflammatory response, and NLR is other index of systemic inflammation \[[@R16]\]. Previous studies have shown that serum CRP and NLR are predictors of prognosis in several cancers, including EC \[[@R8]--[@R10]\]. Recently, we conducted two meta-analyses \[[@R17], [@R18]\] revealed that CRP and NLR were significantly associated with prognosis in patients with EC. In the current study, however, CRP or NLR were not independent prognostic factors in multivariate analyses.

Recently, the CRP/Alb ratio was reported to correlate with prognosis in patients with various cancers, including EC \[[@R13]--[@R15]\]. Wei \[[@R14]\] and Xu \[[@R15]\] revealed that CRP/Alb ratio is a novel and usefull predictive factor in patients with ESCC. In the current study, CRP/Alb ratio was still an independent prognostic factor (*P* \< 0.001). In the current study, therefore, we firstly investigated the prognostic significance of NLR/Alb ratio in ESCC patients. Recently, Camp \[[@R19]\] initial developed a graphical method, named X-tile, to illustrate a method of dividing a single cohort into training and validation subsets. They concluded that the X-tile plot can present a new tool for the assessment of biological relationships and discover cut-points based on marker expression. After that, more and more researchers have revealed that the X-tile is a robust graphical tool, to determine the optimal cut-off values \[[@R20]--[@R22]\]. In the current study, the optimal cut-off value for NLR/Alb was calculated by the X-tile program, which was 0.1. Kaplan--Meier analyses demonstrated that there was a significantly better 5-year CSS in patients with NLR/Alb ≤ 0.1 than patients with NLR/Alb \> 0.1 (39.1% vs. 11.0%, *P* \< 0.001). Multivariate analyses revealed that NLR/Alb (*P* = 0.001) was an independent prognostic factor.

In the current study, the GPS, a well-known inflammatory parameter, was not an independent prognostic factor. NLR/Alb (*P* = 0.001) and CRP/Alb (*P* \< 0.001) were significant independent predictors for CSS. The areas under the curve (AUC) was 0.702 (95% CI: 0.635--0.763, *P* \< 0.001) for CRP/Alb and 0.678 (95% CI: 0.574--0.716, *P* \< 0.001) for NLR/Alb, respectively. The discrimination ability of the NLR/Alb was similar to CRP/Alb, indicating that NLR/Alb predicts survival in ESCC similar to CRP/Alb.

There is no consensus for the standard treatment for EC. However, esophagectomy with lymph node dis remains the standard treatment for patients with early stage. Recent trials, including CROSS, MAGIC, ACCORD and OEO2, have established neoadjuvant therapy as standard of care for locally advanced esophageal cancer \[[@R23]--[@R27]\]. In addition, studies have demonstrated that postoperative adjuvant chemoradiotherapy significantly improves the long-term survival of patients with EC compared with surgery alone \[[@R28], [@R29]\]. However, the current study was a retrospective study between 2005 and 2008, the preoperative adjuvant radiotherapy and/or chemotherapy was controversial at the time. On the other hand, patients who received preoperative neoadjuvant treatment were excluded because neoadjuvant therapy will have an important impact on the inflammation. However, no significant difference was found regarding 5-year CSS in adjuvant therapy in our study. Two possible reasons were as follows: Firstly, the postoperative adjuvant chemoradiotherapy was not mandatory in our study. Secondly, most of patients with postoperative adjuvant therapy were locally advanced disease.

Several limitations should be acknowledged in the current study. Firstly, the current study was a retrospective study with a small sample. Secondly, in our study, we excluded patients who had received neoadjuvant treatment, which may have influenced the result. The results of the study should therefore be regarded with caution. Therefore, larger prospective studies will need to be performed to confirm the prognostic value for NLR/Alb ratio. 

In summary, based on the findings of the current study, the NLR/Alb ratio is a usefull and independent predictive factor in patients with ESCC. The NLR/Alb is easy to measure routinely because of its low cost and convenience, which can be used in clinical practice as a sensitive cancer biomarker. We also conclude that 0.1 may be the optimal cut-off point for NLR/Alb ratio in predicting CSS in patients with ESCC.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

Between January 2005 and December 2008, a total of 329 consecutive cases with resectable ESCC were included in the current retrospective study. The eligibility criteria were included: (1) ESCC was confirmed by histopathological examination; (2) curative surgery with margins histologically free of disease; and (3) preoperative serum NLR, CRP and Alb were obtained before surgery within one week. Exclusion criteria were as follows: patients who received preoperative neoadjuvant treatment, patients who had distant metastasis and those who had any form of acute infection or chronic inflammatory disease.

Treatment {#s4_2}
---------

All patients underwent curative esophagectomy. The standard surgical approach included the Ivor Lewis and the McKeown procedure with two-field or three-field lymphadenectomy \[[@R23], [@R24]\]. Patients who had received neoadjuvant therapy were excluded in the current study. As the role of postoperative adjuvant treatment was controversial during that period, adjuvant therapy was not mandatory. The most frequent adjuvant chemotherapy included cisplatin and 5-fluorouracil. The median postoperative radiation dose was 50 Gy.

Data collection {#s4_3}
---------------

Blood samples were obtained before surgery to measure CRP, neutrophil count, lymphocyte count and albumin levels. Data on preoperative laboratory examination were extracted in our medical records. The serum levels of NLR, CRP, Alb, NLR/Alb and CRP/Alb were taken within one week prior to surgery.

Follow-up {#s4_4}
---------

The patients in the current study were staged according to the 7th edition of the American Joint Committee on Cancer Cancer Staging \[[@R30]\]. The study was approved by the Ethics Committees of Zhejiang Cancer Hospital. In the current study, a cancer-specific survival (CSS) analysis was ascertained. The last follow-up was 30 June 2013.

Statistical analysis {#s4_5}
--------------------

The optimal cut-off values for NLR, CRP, albumin, CRP/Alb and NLR/Alb were calculated by a X-tile program \[[@R19]\]. Pearson correlation analyses were performed to calculate the correlation among CRP, NLR, Alb, CRP/Alb and NLR/Alb. A *t*-test and chi-squared test were used to determine the significance of differences for patients grouped by NLR/Alb. Kaplan--Meier methods were used to analyse CSS. Univariate and multivariate analyses were performed to analyse the prognostic factors. A receiver operating characteristic (ROC) curve for CSS prediction was plotted. The area under curve (AUC) was used as an estimation of diagnostic accuracy. Statistical analyses were conducted with SPSS 17.0 (SPSS Inc., Chicago, IL, USA).
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